• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Luna Innovations Acquires OptaSense

Share:

December 8, 2020

Highlights on this story:
  • Acquisition combines two global leaders in fiber optic sensing solutions
  • OptaSense’s market-leading position in distributed acoustic sensing (DAS) combined with Luna’s suite of sensing products forms the industry’s most comprehensive portfolio
  • OptaSense’s diverse, blue-chip customer base aligns well with Luna’s; presents a significant opportunity for expansion of offerings into both customer groups
  • Transformative acquisition allows Luna to cost-effectively establish a strong international presence and adds to its U.S. leadership position
  • OptaSense allows for expansion into high-growth markets such as security and perimeter detection, smart infrastructure monitoring and oil and gas; expected to accelerate Luna’s data services and IOT strategy
  • Acquisition expected to be accretive in 2021

Luna Innovations Inc. (NASDAQ: LUNA), a global leader in advanced optical technology, today announced it has acquired OptaSense Holdings, Ltd. (“OptaSense”), a QinetiQ company (LON: QQ), for 29 million British Pounds in cash. OptaSense is a recognized market leader in fiber optic distributed monitoring solutions for pipelines, oilfield services, security, highways and railways, as well as power and utilities monitoring systems. The combination is expected to create the world’s largest fiber optic sensing company.
“The acquisition of OptaSense marks an incredibly important milestone in Luna’s history and will further support our growth trajectory,” said Scott Graeff, President and Chief Executive Officer of Luna. “With the combination of Luna and OptaSense, we are bringing together businesses with strong adjacencies and a large, combined opportunity. This transaction allows Luna to acquire a leader in fiber optic sensing solutions and distributed acoustic sensing systems of a global size and scale that will truly be transformative to our company. In addition, OptaSense’s success has been driven by a world class, industry-leading technology base and a very talented team of employees. We are very excited about welcoming them to the Luna team.”

The acquisition provides Luna with important distributed acoustic sensing (DAS) intellectual property and products, which strongly complement Luna’s existing portfolio, and provides algorithm-development expertise, critical for AI and machine learning. OptaSense’s research and development talent and highly skilled salesforce, combined with more than 150 active and pending patents, will also enhance Luna’s existing experienced team and broaden its intellectual property portfolio.

Steve Wadey, QinetiQ Chief Executive Officer, said “We are delighted to announce the sale of OptaSense to Luna, who will provide greater synergies and relevant market access to enable and accelerate their future growth.”

OptaSense will become a fully owned subsidiary of Luna Innovations Incorporated, while continuing to operate under its existing brand for the foreseeable future, and OptaSense employees will remain within the company, with offices in the United Kingdom, Dubai, the United States and Canada.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

B. Riley Securities served as financial advisor and Cooley LLP served as legal advisor to Luna.

Compelling Strategic Benefits

Luna expects that this transformative acquisition will:

  • Provide Luna with important Distributed Acoustic Sensing (“DAS”) intellectual property, products and expertise. DAS strongly complements Luna’s existing offerings, and provides algorithm development expertise, critical for AI and machine learning.
  • Bring a diverse, blue-chip customer base with limited crossover with Luna’s customer base. This represents a significant opportunity for expansion into both customer groups.
  • Enhance Luna’s existing sales team and broad intellectual property portfolio through its R&D expertise and highly skilled salesforce, combined with more than 150 patents active and pending.
  • Allow Luna to cost-effectively establish a strong operational presence internationally, building upon its already strong international customer base and sales capability.
  • Rapidly generate expansion opportunities into high-growth markets such as security and perimeter detection, smart infrastructure monitoring and oil and gas,
  • Realize efficiencies and leverage the combination of OptaSense and Luna to grow rapidly Luna’s operations, customer base, offerings, and financial profile.

Transaction Terms and Financing

Luna is acquiring OptaSense for £29 million, which required approximately $40 million in cash. The transaction was funded using roughly $20 million of Luna’s existing cash and $20 million in debt (the source for which is discussed in a separate press release issued this morning).

2020 Full-Year Outlook

Luna is reaffirming its full-year 2020 guidance:

  • Total revenues of $81M to $83M
  • Adjusted EBITDA of $10M to $12M

The company expects to provide an additional outlook as well as additional qualitative detail on its fourth quarter and year-end 2020 earnings call, the date for which will be announced early next year.

Non-GAAP Financial Measures

In evaluating the operating performance of its business, Luna’s management considers Adjusted EBITDA, which excludes certain charges and credits that are required by GAAP. Adjusted EBITDA provide[s] useful information to both management and investors by excluding the effect of certain non-cash expenses and items that Luna believes may not be indicative of its operating performance, because either they are unusual and Luna does not expect them to recur in the ordinary course of its business, or they are unrelated to the ongoing operation of the business in the ordinary course. Adjusted EBITDA should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Jakarta-Based Digital Clinic Obtains $5M and More Digital Health Fundings.Jakarta-Based Digital Clinic Obtains $5M and More Digital Health Fundings.
  • Genesis Drug Discovery and Development Expands Its Presence in the Clinical Space by Acquiring STATKING Clinical ServicesGenesis Drug Discovery and Development Expands Its Presence in the Clinical Space by Acquiring STATKING Clinical Services
  • Global Psychedelic Drugs Market Research Report 2021: Analysis By Drug, Route of Administration, Distribution Channel, Pipeline Drugs and Forecast to 2026Global Psychedelic Drugs Market Research Report 2021: Analysis By Drug, Route of Administration, Distribution Channel, Pipeline Drugs and Forecast to 2026
  • Olive Secures $400M at a $4B Valuation to Support New Instant Claim Payment SolutionOlive Secures $400M at a $4B Valuation to Support New Instant Claim Payment Solution
  • Drug Pricing Reform Includes a Focus on Patents: Here’s How Pharma Can PrepareDrug Pricing Reform Includes a Focus on Patents: Here’s How Pharma Can Prepare
  • GSK snares top pharma honors at Lions Health with first Grand Prix in yearsGSK snares top pharma honors at Lions Health with first Grand Prix in years
  • RealSelf Acquires Tajmeeli.com to serve Arabic-Speaking Medical Aesthetics MarketRealSelf Acquires Tajmeeli.com to serve Arabic-Speaking Medical Aesthetics Market
  • Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolioNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications